Cardurion
Burlington, US · Founded 2017 · 74 employees on LinkedIn · 4 known investors
Cardurion is a cardiovascular disease-focused company developing therapeutics, with a pipeline advanced through clinical development, trial design, regulatory affairs, and commercialization. It draws on a board of cardiovascular disease experts and industry veterans to guide its drug development.
Founders & leadership
Cardurion was founded in 2017 by Michael E. Mendelsohn and Michael Mendelsohn, M.D..
ME
Michael E. MendelsohnFounder and Chief Strategy Officer
MM
Investors · 4
Frequently asked questions
- What does Cardurion do?
- Cardurion is a cardiovascular disease-focused company developing therapeutics, with a pipeline advanced through clinical development, trial design, regulatory affairs, and commercialization. It draws on a board of cardiovascular disease experts and industry veterans to guide its drug development.
- Who founded Cardurion?
- Cardurion was founded by Michael E. Mendelsohn, Michael Mendelsohn, M.D. in 2017.
- Who are Cardurion's investors?
- Cardurion's investors include Bain Capital, Delos Capital, Digitalis Ventures, New Enterprise Associates (NEA).
- Where is Cardurion headquartered?
- Cardurion is headquartered in Burlington, US.